Skip to main content

Corticosteroid Pharmacokinetics in Liver Disease

Clinical Pharmacokinetics volume 4, pages 233–240 (1979)Cite this article

Summary

Among the corticosteroids, prednisone is the most commonly used in the treatment of chronic active liver disease. However, its pharmacokinetics have only recently been investigated. Prednisone is effectively absorbed and converted to its active therapeutic derivative, prednisolone, in healthy volunteers and in patients with liver disease; the bioavailability of oral prednisone approximates 100% of an intravenous dose and is comparable after administration of either prednisone or prednisolone. Patients with liver disease and hypoalbuminaemia are more likely to suffer major side effects of prednisone as a consequence of decreased protein binding and delayed clearance of prednisolone. Dosage in such patients should be reduced in accordance with serum albumin concentration.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  • Bacon, G.E.: Measurement of plasma prednisolone by gas chromatography. Journal of Laboratory Clinical Medicine 73: 1030–1035 (1969).

    CAS  Google Scholar 

  • Blitzer, B.L.; Mutchnick, M.G.; Joshi, PH.; Phillips, M.M.; Fessel, J.M. and Conn, H.O.: Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. American Journal of Digestive Diseases 22: 477–484 (1977).

    CAS  Google Scholar 

  • Campra, J.L.; Hamlin, E.M.; Kirshbaum, R.J.; Olivier, M.; Redeker, A.G. and Reynolds, T.B.: Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Annals of Internal Medicine 79: 625–631 (1973).

    CAS  Google Scholar 

  • Centeno, F.; Robles, G.; Uribe, M.; Gil-Lozada, S. and Suarez, G.I.: Nomogram for prednisone-prednisolone adjustment dose in patients with hypoalbuminemia. Revista de Investigacion Clinica (Mex) 32: 35–39 (1978).

    Google Scholar 

  • Comb, G.: Therapy of fulminant hepatitis. Postgraduate symposium on viral hepatitis. The American Association for the Study of Liver Diseases (Chicago, November 3 1976).

  • Colburn, W.A.: Radioimmunoassay for prednisone. Steroids 24: 95–106 (1974).

    PubMed  Article  CAS  Google Scholar 

  • Colburn, W.A. and Buller, R.H.: Radioimmunoassay for prednisolone. Steroids 21: 833–846 (1973).

    PubMed  Article  CAS  Google Scholar 

  • Cook, G.C.; Mulligan. R. and Sherlock, S.: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Quarterly Journal of Medicine 40: 159–185 (1971).

    PubMed  CAS  Google Scholar 

  • Davis, M.; Williams, R.; Chakraborty, J.; English, J.; Marks, V.; Ideo, G. and Tempini, S.: Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. British Journal of Clinical Pharmacology 5: 501 (1978).

    PubMed  Article  CAS  Google Scholar 

  • Fanghanel, G.; Blitz, I.; Uribe, M. and Morato, T.: Determinacion de Cortisol y globulina transportadora de Cortisol en normales, embarazadas, sindrome de malabsorcion y cirrhosis hepatica. Revista de Investigacion Clinica (Mex) 28: 151–158 (1976).

    CAS  Google Scholar 

  • Gregory, P.B.; Knauer, C.M.; Kempson, R.L. and Miller, R.: Steroid therapy in severe viral hepatitis: A double blind, randomized trial of methyl-prednisolone versus placebo. New England Journal of Medicine 294; 681–687 (1976).

    PubMed  Article  CAS  Google Scholar 

  • Helman, R.A.; Temki, M.H.; Nye, S.W. and Fallon, J.H.: Alcoholic hepatitis: Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine 74: 311–321 (1971).

    PubMed  CAS  Google Scholar 

  • Jenkins, J.S. and Sampson, P.A.: Conversion of cortisone to Cortisol and prednisone to prednisolone. British Medical Journal 2: 205–207 (1967).

    PubMed  Article  CAS  Google Scholar 

  • Jick, H.: What to expect from prednisone. Drug Therapy 5: 85–91 (1975).

    Google Scholar 

  • Kozower, M.; Veathch, L. and Kaplan, M.M.: Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects. Journal of Clinical Endocrinology and Metabolism 38: 407–412 (1974).

    PubMed  Article  CAS  Google Scholar 

  • Lewis, G.P.; Jusko, W.J.; Burke, C.W. and Graves, L.: Prednisone side-effects and serum protein levels. Lancet 2: 778 (1971).

    PubMed  Article  CAS  Google Scholar 

  • Murray-Lyon, I.M.; Stern, R.B. and Williams, R.: Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1: 735–737 (1973).

    PubMed  Article  CAS  Google Scholar 

  • Peterson, R.E.: Adrenocortical steroid metabolism and adrenal cortical function in liver disease. Journal of Clinical Investigation 39: 320–321 (1960).

    PubMed  Article  CAS  Google Scholar 

  • Pickup, M.E.: Clinical pharmacokinetics of prednisone and prednisolone. Clinical Pharmacokinetics 4: 111–128 (1979).

    PubMed  Article  CAS  Google Scholar 

  • Porter, M.P.; Simon, F.R.; Pope, C.E.; Volwiler, W. and Fenster, L.F.: Corticosteroid therapy in severe alcoholic hepatitis: A double-blind drug trial. New England Journal of Medicine 284: 1350–1355 (1971).

    PubMed  Article  CAS  Google Scholar 

  • Powell, L.W. and Axelsen, E.: Corticosteroids in liver diseases: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut 13: 690–696 (1972).

    PubMed  Article  CAS  Google Scholar 

  • Robles, G.; Gil, S. and Uribe, M.: Receptores de corticosteroides en linfocitos de pacientes con hepatitis cronica activa. Proceedings of the XI Meeting of the Sociedad Mexicana de Gastroenterologia, p. 31 (Mexico, 1977).

    Google Scholar 

  • Sandberg, D.H.; Bacallao, C.Z. and Cleveland, W.W.: Measurement of plasma prednisolone by a competitive protein-binding assay. Biochemical Medicine 4: 383–390 (1970).

    PubMed  Article  CAS  Google Scholar 

  • Schalm, S.W.; Ammon, H.V. and Summerskill, W.H.J.: Failure of customary treatment in chronic active liver disease: Causes and management Annals of Clinical Research 8: 221–227 (1976a).

    PubMed  CAS  Google Scholar 

  • Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Development of radioimmunoassays for prednisone and prednisolone: application to studies of hepatic metabolism of prednisone. Mayo Clinic Proceedings 51: 761–766 (1976b).

    PubMed  CAS  Google Scholar 

  • Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Prednisone for chronic active liver disease: Pharmacokinetics, including conversion to prednisolone. Gastroenterology 72: 910–913 (1977).

    PubMed  CAS  Google Scholar 

  • Schedl, H.P.: Steroid hormone metabolism in liver disease; in Popper and Schaffner (Eds) Progress in Liver Disease, volume II, p. 104 (Grune and Stratton, New York 1965).

    Google Scholar 

  • Sherlock, S.: Chronic hepatitis. Gut 15: 581–597 (1974).

    PubMed  Article  CAS  Google Scholar 

  • Sherlock, S.; Fox, R.A.; Niazi, S.P. and Schuerer, P.: Chronic liver disease and primary liver cell cancer with hepatitis-associated (Australia) antigen in serum. Lancet 1: 1243–1247 (1970).

    PubMed  Article  CAS  Google Scholar 

  • Soloway, R.D.; Summerskill, W.H.J.; Baggenstoss, A.H.; Geal, M.G.; Gitnick, G.L.; Elveback, L.R. and Schoenfield, L.J.: Clinical biochemical and histological remission of severe chronic active liver disease: a controlled study of treatments on early prognosis. Gastroenterology 63: 820–833 (1972).

    PubMed  CAS  Google Scholar 

  • Summerskill, W.H.J.; Korman, M.G.; Ammon, H.V. and Baggenstoss, A.H.: Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16: 876–883 (1975).

    PubMed  Article  CAS  Google Scholar 

  • Uribe, M.: Absorcion y disponibilidad biologica de las drogas. Revista Mexicana de Gastroenterologia 42: 2–8 (1978).

    Google Scholar 

  • Uribe, M.: Go, V.L.W. and Summerskill, W.H.J.: Kinetics and interconversion of prednisone and prednisolone compared in chronic active liver disease (CALD) after oral doses (Abstract). Gastroenterology 71: 932 (1976b).

    Google Scholar 

  • Uribe, M.; Go, V.L.W. and Summerskill, W.H J.: Prednisone and peptic ulcer in chronic liver disease. New England Journal of Medicine 296: 173 (1977a).

    PubMed  CAS  Google Scholar 

  • Uribe, M.; Go, V.L.W. and Summerskill, W.H.J.: Why hypoalbuminemia and hyperbilirubinemia predisposes to steroid side effects (Abstract). Gastroenterology 72: 1143 (1977b).

    Google Scholar 

  • Uribe, M.; Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Effect of liquid diet on serum protein binding and prednisolone concentrations after oral prednisone. Gastroenterology 71: 362–364 (1976a).

    PubMed  CAS  Google Scholar 

  • Uribe, M.; Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut 19: 1131–1135 (1978).

    PubMed  Article  CAS  Google Scholar 

  • Uribe, M.; Wolf; A. and Summerskill, W.H.J.: Steroid side effects during therapy of chronic active liver disease: What to expect (Abstract). Gastroenterology 71: 932 (1976c).

    Google Scholar 

Download references

Author information

Affiliations

  1. Liver Unit, Instituto National de la Nutricion, Hospital de Enformedades de la Nutricion, Mexico City, Mexico

    Misael Uribe &  Vay Liang W. Go

  2. Gastroenterology Unit, Mayo Clinic, Rochester, Minnesota, USA

    Misael Uribe &  Vay Liang W. Go

Authors
  1. Misael Uribe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vay Liang W. Go
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Uribe, M., Go, V.L.W. Corticosteroid Pharmacokinetics in Liver Disease. Clin Pharmacokinet 4, 233–240 (1979). https://doi.org/10.2165/00003088-197904030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-197904030-00005

Keywords

  • Prednisone
  • Prednisolone
  • Alcoholic Hepatitis
  • Major Side Effect
  • Acute Viral Hepatitis